{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:41:49Z","timestamp":1773081709912,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00066-021-01885-z","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:04:01Z","timestamp":1642723441000},"page":"773-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluating dosimetric parameters predictive of hematologic toxicity in cervical cancer patients undergoing definitive pelvic chemoradiotherapy"],"prefix":"10.1007","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-3996","authenticated-orcid":false,"given":"Elham","family":"Rahimy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"von Eyben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitre","family":"Hristov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"issue":"2","key":"1885_CR1","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn\u00a0M et\u00a0al (2020) Estimates of incidence and mortality of cervical cancer in 2018: a\u00a0worldwide analysis. Lancet Glob Health 8(2):e191\u2013e203","journal-title":"Lancet Glob Health"},{"issue":"35","key":"1885_CR2","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration","year":"2008","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a\u00a0systematic review and meta-analysis of individual patient data from 18 randomized trials. J\u00a0Clin Oncol 26(35):5802\u20135812","journal-title":"J Clin Oncol"},{"issue":"3","key":"1885_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ijrobp.2009.11.040","volume":"79","author":"JA Hayman","year":"2011","unstructured":"Hayman\u00a0JA et al (2011) Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging. Int J Radiat Oncol Biol Phys 79(3):847\u2013852","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1885_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ijrobp.2016.11.027","volume":"97","author":"LK Mell","year":"2017","unstructured":"Mell\u00a0LK et al (2017) Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2). Int J Radiat Oncol Biol Phys 97(3):536\u2013545","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"35","key":"1885_CR5","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration","year":"2008","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a\u00a0systematic review and meta-analysis of individual patient data from 18 randomized trials. J\u00a0Clin Oncol 26(35):5802\u20135812","journal-title":"J Clin Oncol"},{"issue":"15","key":"1885_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","volume":"340","author":"HM Keys","year":"1999","unstructured":"Keys\u00a0HM et\u00a0al (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N\u00a0Engl J Med 340(15):1154\u20131161","journal-title":"N Engl J Med"},{"issue":"3","key":"1885_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","volume":"19","author":"SM de Boer","year":"2018","unstructured":"de Boer\u00a0SM et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19(3):295\u2013309","journal-title":"Lancet Oncol"},{"issue":"9","key":"1885_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","volume":"20","author":"SM de Boer","year":"2019","unstructured":"de Boer\u00a0SM et al (2019) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a\u00a0randomised phase 3 trial. Lancet Oncol 20(9):1273\u20131285","journal-title":"Lancet Oncol"},{"issue":"4","key":"1885_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.adro.2019.06.005","volume":"4","author":"JM David","year":"2019","unstructured":"David\u00a0JM et al (2019) 18F-FDG PET predicts hematologic toxicity in patients with locally advanced anal cancer treated with chemoradiation. Adv Radiat Oncol 4(4):613\u2013622","journal-title":"Adv Radiat Oncol"},{"issue":"15","key":"1885_CR10","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.19.02381","volume":"38","author":"AR Yeung","year":"2020","unstructured":"Yeung\u00a0AR et al (2020) Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study. J\u00a0Clin Oncol 38(15):1685\u20131692","journal-title":"J Clin Oncol"},{"key":"1885_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.07.2069","volume-title":"Phase III randomized trial of postoperative adjuvant conventional radiation (3DCRT) versus image guided intensity modulated radiotherapy (IG-IMRT) in cervical cancer (PARCER): final analysis","author":"S Chopra","year":"2020","unstructured":"Chopra\u00a0S et al (2020) Phase III randomized trial of postoperative adjuvant conventional radiation (3DCRT) versus image guided intensity modulated radiotherapy (IG-IMRT) in cervical cancer (PARCER): final analysis. American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting."},{"issue":"6","key":"1885_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12094-017-1771-6","volume":"20","author":"YM Zhou","year":"2018","unstructured":"Zhou\u00a0YM et al (2018) The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation. Clin Transl Oncol 20(6):713\u2013718","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"1885_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ijrobp.2011.09.048","volume":"83","author":"BS Rose","year":"2012","unstructured":"Rose\u00a0BS et\u00a0al (2012) Correlation between radiation dose to \u00b98F\u2011FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 83(4):1185\u20131191","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1885_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13014-020-01606-3","volume":"15","author":"J Huang","year":"2020","unstructured":"Huang\u00a0J et al (2020) Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a\u00a0single-center prospective randomized controlled trial. Radiat Oncol 15(1):180","journal-title":"Radiat Oncol"},{"issue":"5","key":"1885_CR15","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.ijrobp.2006.03.018","volume":"66","author":"LK Mell","year":"2006","unstructured":"Mell\u00a0LK et al (2006) Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 66(5):1356\u20131365","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1885_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/0284186X.2017.1377847","volume":"57","author":"C Freese","year":"2018","unstructured":"Freese\u00a0C et al (2018) The volume of PET-defined, active bone marrow spared predicts acute hematologic toxicities in anal cancer patients receiving concurrent chemoradiotherapy. Acta Oncol 57(5):683\u2013686","journal-title":"Acta Oncol"},{"key":"1885_CR17","doi-asserted-by":"publisher","first-page":"6285","DOI":"10.2147\/CMAR.S195989","volume":"11","author":"T Kumar","year":"2019","unstructured":"Kumar\u00a0T et\u00a0al (2019) Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation. Cancer Manag Res 11:6285\u20136297","journal-title":"Cancer Manag Res"},{"issue":"2","key":"1885_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ijrobp.2016.10.010","volume":"97","author":"AY Lee","year":"2017","unstructured":"Lee\u00a0AY et\u00a0al (2017) Hematologic nadirs during chemoradiation for anal cancer: temporal characterization and dosimetric predictors. Int J Radiat Oncol Biol Phys 97(2):306\u2013312","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1885_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1200\/GO.20.00079","volume":"7","author":"LM Burt","year":"2021","unstructured":"Burt\u00a0LM et al (2021) Cervix cancer in sub-saharan Africa: an assessment of cervical cancer management. JCO Glob Oncol 7:173\u2013182","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"1885_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijrobp.2009.10.075","volume":"79","author":"K Lim","year":"2011","unstructured":"Lim\u00a0K et al (2011) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 79(2):348\u2013355","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1885_CR21","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/j.prro.2018.10.009","volume":"9","author":"MM Kozak","year":"2019","unstructured":"Kozak\u00a0MM et\u00a0al (2019) Less than whole uterus irradiation for locally advanced cervical cancer maintains locoregional control and decreases radiation dose to bowel. Pract Radiat Oncol 9(2):e164\u2013e171","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"1885_CR22","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","volume":"70","author":"LK Mell","year":"2008","unstructured":"Mell\u00a0LK et al (2008) Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 70(5):1431\u20131437","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1885_CR23","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.21037\/jtd.2017.05.34","volume":"9","author":"SY Chen","year":"2017","unstructured":"Chen\u00a0SY, Feng\u00a0Z, Yi\u00a0X (2017) A general introduction to adjustment for multiple comparisons. J\u00a0Thorac Dis 9(6):1725\u20131729","journal-title":"J Thorac Dis"},{"issue":"1","key":"1885_CR24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani\u00a0R (1996) Regression shrinkage and selection via the Lasso. J\u00a0R Statist Soc\u00a0B 58(1):267","journal-title":"J. R. Statist. Soc. B"},{"issue":"3","key":"1885_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/1754-9485.12297","volume":"59","author":"H Zhu","year":"2015","unstructured":"Zhu\u00a0H et\u00a0al (2015) Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy. J\u00a0Med Imaging Radiat Oncol 59(3):386\u2013393 (quiz 394)","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1885_CR26","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2021) SEER 18 2011\u20132017. https:\/\/seer.cancer.gov\/statfacts\/html\/cervix.html. Accessed 04.2021"},{"issue":"3","key":"1885_CR27","first-page":"617","volume":"33","author":"FE Yang","year":"1995","unstructured":"Yang\u00a0FE et\u00a0al (1995) Analysis of weekly complete blood counts in patients receiving standard fractionated partial body radiation therapy. Int J Radiat Oncol Biol Phys 33(3):617\u2013617","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1885_CR28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.nucmedbio.2006.09.005","volume":"33","author":"Y Murata","year":"2006","unstructured":"Murata\u00a0Y et al (2006) Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET\/CT. Nucl Med Biol 33(8):999\u20131004","journal-title":"Nucl Med Biol"},{"issue":"6","key":"1885_CR29","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s11307-013-0629-8","volume":"15","author":"S Kershah","year":"2013","unstructured":"Kershah\u00a0S et\u00a0al (2013) Comparison of standardized uptake values in normal structures between PET\/CT and PET\/MRI in an oncology patient population. Mol Imaging Biol 15(6):776\u2013785","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"1885_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.ijrobp.2009.12.025","volume":"79","author":"K Albuquerque","year":"2011","unstructured":"Albuquerque\u00a0K et al (2011) Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys 79(4):1043\u20131047","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1885_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijrobp.2013.01.017","volume":"86","author":"AH Klopp","year":"2013","unstructured":"Klopp\u00a0AH et\u00a0al (2013) Hematologic toxicity in RTOG 0418: a\u00a0phase 2\u00a0study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys 86(1):83\u201390","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1885_CR32","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.ijrobp.2008.04.046","volume":"71","author":"LK Mell","year":"2008","unstructured":"Mell\u00a0LK et al (2008) Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 71(5):1504\u20131510","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1885_CR33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ijrobp.2009.11.010","volume":"79","author":"BS Rose","year":"2011","unstructured":"Rose\u00a0BS et\u00a0al (2011) Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 79(3):800\u2013807","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1885_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/sim.4780030207","volume":"3","author":"FE Harrell","year":"1984","unstructured":"Harrell\u00a0FE et\u00a0al (1984) Regression modelling strategies for improved prognostic prediction. Stat Med 3(2):143\u2013152","journal-title":"Stat Med"},{"key":"1885_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12874-016-0144-0","volume":"16","author":"EL Ashbeck","year":"2016","unstructured":"Ashbeck\u00a0EL, Bell\u00a0ML (2016) Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data. BMC Med Res Methodol 16:43","journal-title":"BMC Med Res Methodol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01885-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-021-01885-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01885-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T17:40:14Z","timestamp":1726508414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-021-01885-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1885"],"URL":"https:\/\/doi.org\/10.1007\/s00066-021-01885-z","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"30 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.\u00a0Rahimy, R.\u00a0von Eyben, J.\u00a0Lewis, D.\u00a0Hristov, and E.\u00a0Kidd declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}